Like AR RNAi, c-Myc RNAi reduced prostate cancer cell survival in androgen ligand-depleted conditions while co-suppression of AR and c-Myc was not more effective than suppression of either protein alone (Figure 2, Figure S1). This evidence concerns the gene MYC and prostate carcinoma.